Ipamorelin research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro receptor-pharmacology and secretagogue-comparator studies. The compound is the synthetic pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 (NNC 26-0161).

In vitro, ipamorelin is an agonist at GHS-R1a, the ghrelin receptor, and is used as a selective comparator against earlier growth-hormone secretagogues that show broader pituitary cross-reactivity in published receptor assays. Three of five residues are non-proteinogenic, which supports metabolic stability in cell-based and membrane-preparation experiments. Assay designs typically record GHS-R1a occupancy, downstream second-messenger readouts, or head-to-head selectivity versus GHRP-class ligands. This listing describes receptor pharmacology in experimental systems only.

The material is offered as a lyophilized vial. Identity data (CAS 170851-70-4, formula C38H49N9O5, molecular weight 711.9 g/mol, PubChem CID 9831659) are listed on the specification table. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥99% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.